UNSPSC 51351623: Estradiol dipropionate

This classification denotes a therapeutic estradiol with the molecular formula C24H32O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NIG5418BXB, chemically known as 3,17beta-dihydroxy-1,3,5(10)-estratriene 3,17-dipropionate but more generally known as estradiol dipropionate, which bears US NIH Compound Identifier 3265. European Medicines Agency schedules Estradiol dipropionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB22244.

Most nations, for tariff and trade purposes, schedule estradiol dipropionate under HS 29372300. As of Q4 2014, ESTRADIOL DIPROPIONATE remains US FDA's Preferred Term for this commodity. Estradiol dipropionate bears US NLM identifiers UMLS ID C0059618 and NCI Concept Code C29770. SMILES: CCC(=O)OC1CCC2C(C1)CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@@H]4OC(=O)CC)C.

UNSPSC 51351623 Estradiol dipropionate, a Commodity code, encompasses pharmaceutical-grade estradiol dipropionate products sourced by state and local health facilities, correctional institutions, and public health agencies through cooperative purchasing agreements. State and local governments procure this hormone-replacement and therapeutic agent as part of broader multi-source generic pharmaceutical contracts that bundle dozens to hundreds of active pharmaceutical ingredients into single master agreements with manufacturers or authorized distributors. The scope includes supply of products meeting current Good Manufacturing Practices (cGMP) certification, FDA compliance, Drug Supply Chain Security Act (DSCSA) requirements, and expiration dates of at least one year from manufacture with minimum six-month shelf life. Issuing bodies include state departments of administration and health, county health departments, municipal clinics, and public correctional facilities, often coordinating through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions to achieve volume discounts and standardized pricing structures.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products, with response due by March 26, 2026. The solicitation explicitly identifies estradiol dipropionate and other hormone-replacement agents as part of the product portfolio, requiring vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent weight), compliance with administrative fee format and EDI capability (10 percent combined), and agreement to a 3 percent administrative fee (5 percent), with vendors required to maintain commercial general liability insurance of $5 million per occurrence and contractual relationships with at least two of the three authorized wholesalers. The contract covers Minnesota and Oregon, with the two-year initial term extendable at MMCAP's discretion.